

**Press Release**

 4<sup>th</sup> June, 2021, Ludhiana

**PBT UP BY 7 % TO RS. 571 CRORES FOR YEAR ENDED MAR 2021**
**PAT UP BY 23 % TO RS. 445 CRORES FOR YEAR ENDED MAR 2021**
**EPS INCREASED TO RS. 76 FROM RS. 63**

IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of pharmaceutical (APIs) and specialty chemicals today posted its financial results for the quarter and year ending 31<sup>st</sup> March 2021.

**Annual Financial Results:**

Particulars	Year ended		Rs Crore %age change
	31.03.2021	31.03.2020	
	Total income	1991	1910
EBIDTA	616	590	4 %
Profit before Tax	571	533	7 %
Profit after Tax	445	361	23 %
EPS in Rupees	76	63	21 %

**Quarterly Financial Results:**

Particulars	Quarter ended		Rs Crore %age change
	31.03.2021	31.03.2020	
	Total income from operations	467	447
EBIDTA	117	142	-18 %
Net Profit before Tax	106	130	-18 %
Net Profit after Tax	75	90	-17 %
EPS in Rupees	13	16	-19 %

*Dr Sanjay Chaturvedi, Chief Executive Officer said "During the year the Company's performance has been satisfactory despite the pandemic situation worldwide".*

*He also added, the Company completed the installation of new manufacturing facilities "Unit VIII" to manufacture **Ibuprofen Derivatives** and other pharma (APIs) products. Dr Chaturvedi further informed that the Company has increased the manufacturing capacity of Ethyl Acetate from **87,000 MTPA to 1,00,000 MTPA**.*

*Talking about future projects, he added that the Company is in the process of setting up of 2 new manufacturing facilities 'Unit - IX' for manufacturing Gabapentin & other pharma (APIs) products; and 'Unit - X' for multiple pharma (APIs) products. These units are being installed at the Company's existing Plant site at Barnala (Punjab) through internal accruals only and the installation of these units are running as per schedule.*

### **About IOL Chemicals and Pharmaceuticals Limited (IOLCP)**

Company was established in 1986, listed on National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164) is one of the leading pharmaceutical (APIs) Company and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and anti-platelets.

The Company's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World's largest producer of the Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system alongwith 17 MW captive Co-Generation plant for self reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including UK, Austria, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Portugal, Poland, Ireland, USA, Australia, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, South Korea, Thailand etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

#### *Disclaimer:*

*This document may contain statement which reflect management's current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to differ materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.*